Private Advisor Group LLC Sells 268 Shares of Shire PLC (SHPG)

Private Advisor Group LLC lowered its position in shares of Shire PLC (NASDAQ:SHPG) by 15.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,514 shares of the biopharmaceutical company’s stock after selling 268 shares during the period. Private Advisor Group LLC’s holdings in Shire were worth $263,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the company. IFP Advisors Inc grew its position in Shire by 13.0% in the 4th quarter. IFP Advisors Inc now owns 754 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 87 shares in the last quarter. Synovus Financial Corp grew its position in Shire by 4.9% in the 4th quarter. Synovus Financial Corp now owns 2,131 shares of the biopharmaceutical company’s stock valued at $372,000 after buying an additional 99 shares in the last quarter. Creative Planning grew its position in Shire by 1.4% in the 4th quarter. Creative Planning now owns 7,151 shares of the biopharmaceutical company’s stock valued at $1,245,000 after buying an additional 101 shares in the last quarter. Hills Bank & Trust Co. grew its position in Shire by 1.7% in the 4th quarter. Hills Bank & Trust Co. now owns 7,621 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 125 shares in the last quarter. Finally, Essex Savings Bank bought a new position in Shire in the 4th quarter valued at about $26,000. Institutional investors and hedge funds own 20.23% of the company’s stock.

NASDAQ:SHPG opened at $179.20 on Friday. Shire PLC has a twelve month low of $123.73 and a twelve month high of $182.47. The company has a debt-to-equity ratio of 0.36, a current ratio of 0.92 and a quick ratio of 0.51. The stock has a market cap of $54.71 billion, a PE ratio of 11.83, a price-to-earnings-growth ratio of 1.54 and a beta of 0.87.



A number of equities analysts recently issued reports on the stock. ValuEngine upgraded shares of Shire from a “sell” rating to a “hold” rating in a research report on Thursday, December 6th. Zacks Investment Research reiterated a “hold” rating on shares of Shire in a research report on Thursday, November 15th. Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the company a “buy” rating in a research report on Thursday, December 20th. BidaskClub lowered shares of Shire from a “buy” rating to a “hold” rating in a research report on Friday, November 30th. Finally, William Blair lowered shares of Shire from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 20th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Shire presently has an average rating of “Buy” and an average price target of $201.60.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://dakotafinancialnews.com/2019/03/15/private-advisor-group-llc-sells-268-shares-of-shire-plc-shpg.html.

Shire Profile

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.

Featured Story: Bollinger Bands

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply